tiprankstipranks
Trending News
More News >
Kromek Group plc (GB:KMK)
:KMK

Kromek Group plc (KMK) AI Stock Analysis

Compare
11 Followers

Top Page

GB

Kromek Group plc

(LSE:KMK)

Rating:56Neutral
Price Target:
6.00p
▲(5.26%Upside)
The overall score of 56 reflects a stock with moderate strengths and notable challenges. Positive corporate events and technical indicators provide optimism, but ongoing financial and profitability issues weigh heavily on the score.

Kromek Group plc (KMK) vs. iShares MSCI United Kingdom ETF (EWC)

Kromek Group plc Business Overview & Revenue Model

Company DescriptionKromek Group plc (KMK) is a leading technology company engaged in the development and production of radiation detection solutions across various sectors. The company's core products and services are centered around the design and supply of high-performance imaging and detection components and systems. Kromek serves a range of industries including medical imaging, nuclear detection, and security screening, providing breakthrough technologies that enable efficient and accurate detection and imaging capabilities.
How the Company Makes MoneyKromek Group plc generates revenue primarily through the sale of its proprietary detection and imaging products. The company operates a multifaceted revenue model that includes direct product sales, long-term supply agreements, and license royalties. Key revenue streams for Kromek include the supply of medical imaging components to equipment manufacturers, provision of nuclear detection systems to governmental and private entities, and the sale of security screening technology to airports and other security-critical infrastructures. Additionally, Kromek engages in strategic partnerships and collaborations, which help to expand its market reach and drive innovation, further contributing to its earnings.

Kromek Group plc Financial Statement Overview

Summary
Kromek Group plc's financial performance shows some improvement in revenue and gross profit margins but continues to face challenges with profitability and cash flow. The balance sheet remains moderately stable with low leverage, yet inefficient capital use is evident from negative returns.
Income Statement
45
Neutral
Kromek Group plc shows a volatile performance in its income statement. While there is a recent increase in revenue from £17.31 million to £19.40 million, the company is still operating at a net loss, with a negative net profit margin. Gross profit margins have improved to 55.2%, indicating better cost management. However, negative EBIT and EBITDA margins highlight ongoing operational challenges.
Balance Sheet
50
Neutral
The balance sheet reflects moderate stability with a debt-to-equity ratio of 0.25, which is relatively low and indicates manageable leverage. However, the equity ratio stands at 70.3%, suggesting a solid equity base. Return on equity is negative due to net losses, indicating inefficiency in using shareholders' capital to generate profits.
Cash Flow
40
Negative
The cash flow statement reveals challenges in cash generation, as indicated by negative operating and free cash flows. Free cash flow has deteriorated further, showing significant cash outflows relative to net income. However, positive financing cash flow suggests reliance on external funding to support operations.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue15.98M19.40M17.31M12.05M10.35M13.12M
Gross Profit7.55M10.71M6.04M3.07M2.65M4.07M
EBITDA734.00K2.93M-1.25M-1.23M-1.74M-14.41M
Net Income-5.92M-3.29M-6.10M-4.92M-5.35M-16.54M
Balance Sheet
Total Assets66.84M70.19M63.88M67.42M70.16M64.66M
Cash, Cash Equivalents and Short-Term Investments577.00K466.00K1.10M5.08M15.60M9.44M
Total Debt16.15M12.29M13.38M11.00M12.86M9.77M
Total Liabilities23.91M20.84M22.35M19.99M20.10M19.59M
Stockholders Equity42.93M49.35M41.52M47.44M50.05M45.07M
Cash Flow
Free Cash Flow-1.38M-7.84M-5.78M-10.29M-7.69M-12.59M
Operating Cash Flow-1.26M-2.80M-504.00K-3.84M-1.62M-126.00K
Investing Cash Flow-4.53M-5.00M-5.27M-6.45M-6.07M-11.21M
Financing Cash Flow3.13M7.18M1.99M-1.23M14.44M-544.00K

Kromek Group plc Technical Analysis

Technical Analysis Sentiment
Negative
Last Price5.70
Price Trends
50DMA
5.87
Negative
100DMA
5.89
Negative
200DMA
5.86
Negative
Market Momentum
MACD
-0.05
Positive
RSI
36.09
Neutral
STOCH
12.84
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:KMK, the sentiment is Negative. The current price of 5.7 is below the 20-day moving average (MA) of 6.08, below the 50-day MA of 5.87, and below the 200-day MA of 5.86, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 36.09 is Neutral, neither overbought nor oversold. The STOCH value of 12.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:KMK.

Kromek Group plc Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
£116.16M21.798.61%0.81%-11.80%-32.11%
GBSDI
72
Outperform
£93.05M27.717.69%-5.19%115.58%
GBGHH
65
Neutral
£165.40M30.384.79%1.19%1.74%359.50%
63
Neutral
£564.00M24.42-6.00%2.45%3.52%-29.29%
GBKMK
56
Neutral
£37.33M-13.12%-9.28%-19.48%
GBXAR
54
Neutral
£99.81M-15.96%-13.04%-387.05%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:KMK
Kromek Group plc
5.70
-1.45
-20.28%
GB:XAR
Xaar plc
126.00
-22.50
-15.15%
GB:GHH
Gooch & Housego
622.00
154.59
33.07%
GB:SOLI
Solid State
205.00
-87.19
-29.84%
GB:SDI
SDI Group
92.00
26.60
40.67%

Kromek Group plc Corporate Events

Business Operations and Strategy
Kromek Group Sees Major Shift in Shareholder Voting Rights
Neutral
Jun 3, 2025

Kromek Group plc has announced a significant change in its shareholder structure, with Canaccord Genuity Group Inc. reducing its voting rights from 9.2856% to 4.9996%. This adjustment in holdings reflects a strategic decision by Canaccord Genuity, potentially impacting Kromek’s market dynamics and investor relations. The change may influence the company’s governance and decision-making processes, affecting stakeholders’ interests.

Business Operations and Strategy
Kromek Group to Host Capital Markets Day and Retail Investor Webinar
Neutral
Jun 3, 2025

Kromek Group plc announced it will host a capital markets day on June 18, 2025, for institutional investors and analysts to outline its growth strategy. The event will feature presentations by the CEO, CFO, and other key management, highlighting the company’s future prospects. Additionally, a retail investor webinar is scheduled for June 25, 2025, to engage with a broader audience. These events aim to strengthen stakeholder engagement and provide insights into Kromek’s strategic direction, potentially impacting its market positioning and investor relations.

Product-Related AnnouncementsBusiness Operations and Strategy
Kromek Group Secures New Orders for D3 Series Detectors
Positive
May 28, 2025

Kromek Group plc has secured two significant orders worth approximately $900k to supply its D3 series detectors to a European and a US customer. These orders, aimed at enhancing radiation detection capabilities, underscore Kromek’s role in global safety and security amid geopolitical uncertainties, further solidifying its position in the critical security market.

Executive/Board ChangesBusiness Operations and Strategy
Kromek Group Announces New CFO Appointment
Positive
May 8, 2025

Kromek Group plc announced a significant leadership change with Claire Burgess appointed as the new Chief Financial Officer and Company Secretary, succeeding Paul Farquhar who is retiring. Burgess brings over 12 years of experience in senior financial roles within the engineering and technology sectors, which aligns with Kromek’s strategic focus on growth in technology and engineering. Her expertise is expected to support Kromek’s ongoing strategy execution, potentially strengthening its market position and operational capabilities.

Business Operations and StrategyFinancial Disclosures
Kromek Group Exceeds FY 2025 Expectations, Eyes Continued Growth
Positive
May 8, 2025

Kromek Group plc announced a successful FY 2025, with revenues and profits exceeding market expectations, driven by a significant partnership with Siemens Healthineers and a recovery in its CBRN Detection segment. The company reduced its debt substantially and anticipates continued revenue growth and profitability in FY 2026, supported by strong contracted revenues and a robust international sales pipeline.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 29, 2025